Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

Trial Profile

A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Infliximab (Primary) ; Ustekinumab (Primary) ; Acitretin; Adalimumab; Antipsoriatics; Ciclosporin; Etanercept; Methotrexate; Psoralens
  • Indications Plaque psoriasis; Psoriasis; Psoriatic arthritis
  • Focus Adverse reactions
  • Acronyms PSOLAR
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 27 Dec 2018 Planned End Date changed from 30 Sep 2029 to 1 Dec 2029.
    • 28 Nov 2018 Planned number of patients changed from 12000 to 16000.
    • 28 Nov 2018 Planned End Date changed from 31 May 2021 to 30 Sep 2029.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top